Forensic Analysis · Healthcare / Pharmaceuticals / Biotech · as of Aug 7, 2026

Arrivent Biopharma, Inc. (AVBP)

A forensic read on Arrivent Biopharma, Inc. built from its complete SEC filings — financial-health screens, earnings quality, red flags and a price-aware rating. Reproducible math, not opinion.

F · Poor — capital at risk

Forensic grade

Grey Zone

Financial health

11.1

Distress distance

Clean

Earnings quality

Forensic signals

-54.1%

ROE

$1.5B

Market cap

This free snapshot doesn't read filing or proxy text, so the auditor-quality and governance checks that can lower a grade were not evaluated (red flags, auditor quality, say on pay, board independence). Those checks only ever lower a grade, so the full analysis can land below the grade above but never above it — treat it as the most favourable reading, not the settled one.

Arrivent Biopharma, Inc. earns an F (Poor — capital at risk) forensic quality grade, and its balance-sheet distress test reads 11.1, placing it in the Grey zone. 2 forensic signals were flagged in its latest SEC filings, led by accruals ratio (% of noa).

What the filings flag

+35.2%

FY2024→FY2025

Accruals ratio (% of NOA). Net operating assets grew +35.2% relative to their own average in FY2025 — scaled by NOA itself, not total assets (see the Forensic Screens card's differently-scaled Sloan Accrual Ratio for that read). Accruals are building sharply — a large slice of profit sits in operating assets, not cash; Richardson/Sloan link high accruals to weaker future returns as they reverse. The cash-flow cross-check is more mixed: reported earnings ran in line with operating cash by 3% of net operating assets, diverging from the balance-sheet accrual read.

n/m (stock split)

FY2023–FY2025

Share count (stock split). Diluted share count changed +1697% over the last 2 years to FY2025, but that includes a large one-time change around FY2024 consistent with a stock split or reverse split, not gradual buybacks or issuance — a split changes the count with NO effect on any holder's proportional ownership, so the raw +323.9%/yr figure isn't a real buyback/dilution read here.

Key fundamentals

Return on Equity-54.1%

The forensic grade and screens above are free — no account needed. Want the AI investment read on top — the 0–100 rating, thesis, bull-vs-bear, red flags and the 12-month scenario, written from Arrivent Biopharma, Inc.'s actual 10-K/10-Q/8-K filings?

Generate the AI investment read →

No credit card · informational only, not investment advice · see the track record

← Browse all forensic stock analyses

Data from SEC EDGAR public filings · metrics as of Aug 7, 2026. Forensic signals flag probability, not certainty.